Latest From Debiopharm Group
Bluebird licenses Inhibrx’s single-domain antibody technology for use in constructs for CAR-T therapy generation. Jazz pays $56m up front under an engineered exosome collaboration with Codiak.
Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.
Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.
- Large Molecule
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Specialty Pharmaceuticals
- Therapeutic Areas
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Debio Group
- Western Europe
- Parent & Subsidiaries
- Debiopharm Group
- Senior Management
Rolland-Yves Mauvernay, Co-Pres.
Thierry Mauvernay, Co-Pres.
- Contact Info
Phone: (41) 21 321 0111
Chemin Messidor 5-7
P.O. Box 5911 Lausanne, CH-1002
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.